摘要
目的研究生长抑素与凝血酶联合治疗乙肝肝硬化伴食管胃底静脉曲张破裂出血(esophageal and gas⁃tric variceal bleeding,EGVB)的临床疗效及不良反应发生情况。方法方便选取2020年5月—2023年11月安顺市紫云苗族布依族自治县人民医院收治的96例乙肝肝硬化伴EGVB患者为研究对象,依据不同治疗方法分为对照组与研究组,各48例,对照组给予生长抑素治疗,研究组在对照组基础上予以凝血酶治疗。比较两组患者临床疗效、输血量、止血时间、再出血发生率及不良反应发生率。结果研究组治疗有效率为95.83%(46/48),高于对照组的79.17%(38/48),差异有统计学意义(χ^(2)=6.095,P<0.05)。研究组输血量少于对照组,止血时间短于对照组,再出血发生率低于对照组,差异有统计学意义(P均<0.05)。两组患者不良反应总发生率比较,差异无统计学意义(P>0.05)。结论在生长抑素基础上联用凝血酶治疗乙肝肝硬化伴EGVB患者,可进一步提高临床疗效、减少输血量、缩短止血时间并减少再出血发生率,安全性良好。
Objective To study the clinical efficacy and adverse reactions of somatostatin combined with thrombin in the treatment of hepatitis B cirrhosis with esophageal and gastric variceal bleeding(EGVB).Methods A total of 96 pa⁃tients with hepatitis B cirrhosis and EGVB treated in People's Hospital of Ziyun Miao Buyi Autonomous County from May 2020 to November 2023 were conveniently selected as the study objects.According to different treatment meth⁃ods,they were divided into control group and study group,48 cases in each group.The control group was treated with somatatin,and the study group was treated with thrombin on the basis of control group.The clinical efficacy,blood transfusion volume,hemostatic time,incidence of rebleeding and incidence of adverse reactions were compared be⁃tween the two groups.Results The effective rate of the study group was 95.83%(46/48)higher than that of the control group 79.17%(38/48),the difference was statistically significant(χ^(2)=6.095,P<0.05).The blood transfusion volume of the study group was less than that of the control group,the hemostasis time was shorter,and the incidence of rebleed⁃ing was lower than that of the control group,the differences were statistically significant(all P<0.05).There was no sig⁃nificant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Somatosta⁃tin combined with thrombin in the treatment of hepatitis B cirrhosis patients with EGVB can further improve the clini⁃cal efficacy,reduce the amount of blood transfusion,shorten the hemostatic time and reduce the incidence of rebleed⁃ing,with good safety.
作者
周丽
夏一丹
廖梦醒
ZHOU Li;XIA Yidan;LIAO Mengxing(Third Department of Internal Medicine,People's Hospital of Ziyun Miao Buyi Autonomous County,Anshun,Guizhou,550800,China)
出处
《中外医疗》
2024年第29期119-121,共3页
China & Foreign Medical Treatment
